PFS (primary endpoint)1
PFS results were assessed by an IRC, based on central laboratory data for M-protein, and central radiologic imaging review using the IMWG criteria. Median follow-up was 11.6 months.1
40% reduction in the risk of disease progression or death in patients treated with SARCLISA + Pd1Back to top
ORR (secondary endpoint)1,a
asCR, CR, VGPR, and PR were evaluated by the IRC using the IMWG response criteria.
bSARCLISA + Pd (95% CI: 52.2%, 68.2%), Pd (95% CI: 27.8%, 43.4%). 95% CI estimated using the Clopper-Pearson method.
cStratified by age (<75 years vs ≥75 years) and number of previous lines of therapy (2 or 3 vs >3) according to interactive response technology.
Median time to first response was 35 days in the SARCLISA + Pd arm vs 58 days in the Pd arm1
CR=complete response; IMWG=International Myeloma Working Group; IRC=independent response committee; ISS=International Staging System; ORR=overall survival; Pd=pomalidomide and dexamethasone; PFS=progression-free survival; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.Back to top View Safety Profile